Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe.
暂无分享,去创建一个
P. Pedrazzoli | D. Blaise | D. Niederwieser | J. Bay | M. Remberger | O. Ringdén | R. Martino | S. Siena | A. Zambelli | D. Niederwieser | S. Lenhoff | C. Bengala | M. Bregni | T. Demirer | J. Peccatori | A. Porcellini | L. Barkholt | G. Massenkeil | R. Martino | S. François | M. Brune | M. Falda | T. Demirer | Salvatore Siena
[1] M. Aglietta,et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. , 2006, Blood.
[2] N. Vogelzang. Treatment options in metastatic renal carcinoma: an embarrassment of riches. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Sormani,et al. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation , 2005, Cancer.
[5] R. Motzer,et al. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development , 2005, BJU international.
[6] J. Hainsworth,et al. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial , 2005 .
[7] T. Zimmerman,et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience , 2005, Bone Marrow Transplantation.
[8] M. Remberger,et al. A Comparison of Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation , 2004, Transplantation.
[9] R. Motzer,et al. Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma , 2004, Clinical Cancer Research.
[10] J. Joseph,et al. Allogeneic stem-cell transplantation for renalcellcancer , 2004 .
[11] G. Dini,et al. Hematopoetic stem cell transplantation for solid tumors in Europe. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] T. Zimmerman,et al. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-γ-producing T cells , 2004, Bone Marrow Transplantation.
[13] D. Blaise,et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. , 2004, Blood.
[14] J. Joseph,et al. Allogeneic stem-cell transplantation for renal-cell cancer. , 2004, The Lancet Oncology.
[15] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[16] P. Pisa,et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma , 2003, Bone Marrow Transplantation.
[17] D. Blaise,et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients , 2002, Bone Marrow Transplantation.
[18] C. Voena,et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. , 2002, Blood.
[19] O. Ringdén,et al. A graft-versus-colonic cancer effect of allogeneic stem cell transplantation , 2001, Bone Marrow Transplantation.
[20] N. Keiding,et al. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling , 2001, Bone Marrow Transplantation.
[21] N Keiding,et al. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis , 2001, Bone Marrow Transplantation.
[22] J. Radich,et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.
[23] W. Linehan,et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.
[24] E. Kimby,et al. Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease , 2000, Leukemia.
[25] M. Remberger,et al. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia , 1999, Bone Marrow Transplantation.
[26] R. Storb,et al. Mixed chimerism: preclinical studies and clinical applications. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[27] A. Ravaud,et al. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .
[28] G. Hortobagyi,et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.
[30] A. Ravaud,et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. , 1998, The New England journal of medicine.
[31] E. Estey,et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.
[32] A. Nagler,et al. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia , 1996, The Lancet.
[33] M. Labopin,et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1996, Bone marrow transplantation.
[34] C. Marth,et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. , 1996, Blood.
[35] A Ferrant,et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.
[36] D. Petrylak,et al. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. , 1995, Seminars in oncology.
[37] S. Rosenberg,et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.
[38] A. Rimm,et al. Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.
[39] R. Truitt,et al. MANIPULATION OF GRAFT‐VERSUS‐HOST DISEASE FOR A GRAFT‐VERSUS‐LEUKEMIA EFFECT AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION IN AKR MICE WITH SPONTANEOUS LEUKEMIA/LYMPHOMA1 , 1986, Transplantation.
[40] R. Storb,et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.